Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease...
Covered in this story
What has happened since
- Labcorp is down 4.7% since this was published, 57 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $LH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Labcorp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.